Copyright Reports & Markets. All rights reserved.

Global Irritable Bowel Syndrome (IBS) Therapeutics Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Irritable Bowel Syndrome (IBS) Therapeutics Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Irritable Bowel Syndrome (IBS) Therapeutics Market Size Growth Rate by Product
      • 1.4.2 Blautix (Strain)
      • 1.4.3 Bekinda (IBS-D)
      • 1.4.4 SYN-010
      • 1.4.5 Tenapanor
    • 1.5 Market by End User
      • 1.5.1 Global Irritable Bowel Syndrome (IBS) Therapeutics Market Size Growth Rate by End User
      • 1.5.2 Hospital
      • 1.5.3 Research
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Irritable Bowel Syndrome (IBS) Therapeutics Market Size
      • 2.1.1 Global Irritable Bowel Syndrome (IBS) Therapeutics Revenue 2014-2025
      • 2.1.2 Global Irritable Bowel Syndrome (IBS) Therapeutics Sales 2014-2025
    • 2.2 Irritable Bowel Syndrome (IBS) Therapeutics Growth Rate by Regions
      • 2.2.1 Global Irritable Bowel Syndrome (IBS) Therapeutics Sales by Regions
      • 2.2.2 Global Irritable Bowel Syndrome (IBS) Therapeutics Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Irritable Bowel Syndrome (IBS) Therapeutics Sales by Manufacturers
      • 3.1.1 Irritable Bowel Syndrome (IBS) Therapeutics Sales by Manufacturers
      • 3.1.2 Irritable Bowel Syndrome (IBS) Therapeutics Sales Market Share by Manufacturers
      • 3.1.3 Global Irritable Bowel Syndrome (IBS) Therapeutics Market Concentration Ratio (CR5 and HHI)
    • 3.2 Irritable Bowel Syndrome (IBS) Therapeutics Revenue by Manufacturers
      • 3.2.1 Irritable Bowel Syndrome (IBS) Therapeutics Revenue by Manufacturers (2014-2019)
      • 3.2.2 Irritable Bowel Syndrome (IBS) Therapeutics Revenue Share by Manufacturers (2014-2019)
    • 3.3 Irritable Bowel Syndrome (IBS) Therapeutics Price by Manufacturers
    • 3.4 Irritable Bowel Syndrome (IBS) Therapeutics Manufacturing Base Distribution, Product Types
      • 3.4.1 Irritable Bowel Syndrome (IBS) Therapeutics Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Irritable Bowel Syndrome (IBS) Therapeutics Product Type
      • 3.4.3 Date of International Manufacturers Enter into Irritable Bowel Syndrome (IBS) Therapeutics Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Irritable Bowel Syndrome (IBS) Therapeutics Sales by Product
    • 4.2 Global Irritable Bowel Syndrome (IBS) Therapeutics Revenue by Product
    • 4.3 Irritable Bowel Syndrome (IBS) Therapeutics Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Irritable Bowel Syndrome (IBS) Therapeutics Breakdown Data by End User

    6 North America

    • 6.1 North America Irritable Bowel Syndrome (IBS) Therapeutics by Countries
      • 6.1.1 North America Irritable Bowel Syndrome (IBS) Therapeutics Sales by Countries
      • 6.1.2 North America Irritable Bowel Syndrome (IBS) Therapeutics Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Irritable Bowel Syndrome (IBS) Therapeutics by Product
    • 6.3 North America Irritable Bowel Syndrome (IBS) Therapeutics by End User

    7 Europe

    • 7.1 Europe Irritable Bowel Syndrome (IBS) Therapeutics by Countries
      • 7.1.1 Europe Irritable Bowel Syndrome (IBS) Therapeutics Sales by Countries
      • 7.1.2 Europe Irritable Bowel Syndrome (IBS) Therapeutics Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Irritable Bowel Syndrome (IBS) Therapeutics by Product
    • 7.3 Europe Irritable Bowel Syndrome (IBS) Therapeutics by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Irritable Bowel Syndrome (IBS) Therapeutics by Countries
      • 8.1.1 Asia Pacific Irritable Bowel Syndrome (IBS) Therapeutics Sales by Countries
      • 8.1.2 Asia Pacific Irritable Bowel Syndrome (IBS) Therapeutics Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Irritable Bowel Syndrome (IBS) Therapeutics by Product
    • 8.3 Asia Pacific Irritable Bowel Syndrome (IBS) Therapeutics by End User

    9 Central & South America

    • 9.1 Central & South America Irritable Bowel Syndrome (IBS) Therapeutics by Countries
      • 9.1.1 Central & South America Irritable Bowel Syndrome (IBS) Therapeutics Sales by Countries
      • 9.1.2 Central & South America Irritable Bowel Syndrome (IBS) Therapeutics Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Irritable Bowel Syndrome (IBS) Therapeutics by Product
    • 9.3 Central & South America Irritable Bowel Syndrome (IBS) Therapeutics by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Irritable Bowel Syndrome (IBS) Therapeutics by Countries
      • 10.1.1 Middle East and Africa Irritable Bowel Syndrome (IBS) Therapeutics Sales by Countries
      • 10.1.2 Middle East and Africa Irritable Bowel Syndrome (IBS) Therapeutics Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Irritable Bowel Syndrome (IBS) Therapeutics by Product
    • 10.3 Middle East and Africa Irritable Bowel Syndrome (IBS) Therapeutics by End User

    11 Company Profiles

    • 11.1 Abbott Laboratories
      • 11.1.1 Abbott Laboratories Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Abbott Laboratories Irritable Bowel Syndrome (IBS) Therapeutics Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Abbott Laboratories Irritable Bowel Syndrome (IBS) Therapeutics Products Offered
      • 11.1.5 Abbott Laboratories Recent Development
    • 11.2 Synergy Pharmaceuticals
      • 11.2.1 Synergy Pharmaceuticals Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Synergy Pharmaceuticals Irritable Bowel Syndrome (IBS) Therapeutics Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Synergy Pharmaceuticals Irritable Bowel Syndrome (IBS) Therapeutics Products Offered
      • 11.2.5 Synergy Pharmaceuticals Recent Development
    • 11.3 Sucampo Pharmaceuticals
      • 11.3.1 Sucampo Pharmaceuticals Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Sucampo Pharmaceuticals Irritable Bowel Syndrome (IBS) Therapeutics Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Sucampo Pharmaceuticals Irritable Bowel Syndrome (IBS) Therapeutics Products Offered
      • 11.3.5 Sucampo Pharmaceuticals Recent Development
    • 11.4 Valeant Pharmaceuticals International
      • 11.4.1 Valeant Pharmaceuticals International Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Valeant Pharmaceuticals International Irritable Bowel Syndrome (IBS) Therapeutics Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Valeant Pharmaceuticals International Irritable Bowel Syndrome (IBS) Therapeutics Products Offered
      • 11.4.5 Valeant Pharmaceuticals International Recent Development
    • 11.5 Ardelyx
      • 11.5.1 Ardelyx Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 Ardelyx Irritable Bowel Syndrome (IBS) Therapeutics Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 Ardelyx Irritable Bowel Syndrome (IBS) Therapeutics Products Offered
      • 11.5.5 Ardelyx Recent Development
    • 11.6 Astellas Pharma
      • 11.6.1 Astellas Pharma Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 Astellas Pharma Irritable Bowel Syndrome (IBS) Therapeutics Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 Astellas Pharma Irritable Bowel Syndrome (IBS) Therapeutics Products Offered
      • 11.6.5 Astellas Pharma Recent Development
    • 11.7 Novartis
      • 11.7.1 Novartis Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 Novartis Irritable Bowel Syndrome (IBS) Therapeutics Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 Novartis Irritable Bowel Syndrome (IBS) Therapeutics Products Offered
      • 11.7.5 Novartis Recent Development
    • 11.8 GlaxoSmithKline
      • 11.8.1 GlaxoSmithKline Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 GlaxoSmithKline Irritable Bowel Syndrome (IBS) Therapeutics Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 GlaxoSmithKline Irritable Bowel Syndrome (IBS) Therapeutics Products Offered
      • 11.8.5 GlaxoSmithKline Recent Development
    • 11.9 Ironwood Pharmaceuticals
      • 11.9.1 Ironwood Pharmaceuticals Company Details
      • 11.9.2 Company Business Overview
      • 11.9.3 Ironwood Pharmaceuticals Irritable Bowel Syndrome (IBS) Therapeutics Sales, Revenue and Gross Margin (2014-2019)
      • 11.9.4 Ironwood Pharmaceuticals Irritable Bowel Syndrome (IBS) Therapeutics Products Offered
      • 11.9.5 Ironwood Pharmaceuticals Recent Development

    12 Future Forecast

    • 12.1 Irritable Bowel Syndrome (IBS) Therapeutics Market Forecast by Regions
      • 12.1.1 Global Irritable Bowel Syndrome (IBS) Therapeutics Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Irritable Bowel Syndrome (IBS) Therapeutics Revenue Forecast by Regions 2019-2025
    • 12.2 Irritable Bowel Syndrome (IBS) Therapeutics Market Forecast by Product
      • 12.2.1 Global Irritable Bowel Syndrome (IBS) Therapeutics Sales Forecast by Product 2019-2025
      • 12.2.2 Global Irritable Bowel Syndrome (IBS) Therapeutics Revenue Forecast by Product 2019-2025
    • 12.3 Irritable Bowel Syndrome (IBS) Therapeutics Market Forecast by End User
    • 12.4 North America Irritable Bowel Syndrome (IBS) Therapeutics Forecast
    • 12.5 Europe Irritable Bowel Syndrome (IBS) Therapeutics Forecast
    • 12.6 Asia Pacific Irritable Bowel Syndrome (IBS) Therapeutics Forecast
    • 12.7 Central & South America Irritable Bowel Syndrome (IBS) Therapeutics Forecast
    • 12.8 Middle East and Africa Irritable Bowel Syndrome (IBS) Therapeutics Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Irritable Bowel Syndrome (IBS) Therapeutics Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      IBS is a chronic disorder characterized by abdominal pain or discomfort associated with altered bowel function for at least three months, according to the Rome III criteria. Patients often experience relapse of symptoms over time.
      The global Irritable Bowel Syndrome (IBS) Therapeutics market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Irritable Bowel Syndrome (IBS) Therapeutics market based on company, product type, end user and key regions.

      This report studies the global market size of Irritable Bowel Syndrome (IBS) Therapeutics in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Irritable Bowel Syndrome (IBS) Therapeutics in these regions.
      This research report categorizes the global Irritable Bowel Syndrome (IBS) Therapeutics market by top players/brands, region, type and end user. This report also studies the global Irritable Bowel Syndrome (IBS) Therapeutics market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      Abbott Laboratories
      Synergy Pharmaceuticals
      Sucampo Pharmaceuticals
      Valeant Pharmaceuticals International
      Ardelyx
      Astellas Pharma
      Novartis
      GlaxoSmithKline
      Ironwood Pharmaceuticals

      Market size by Product
      Blautix (Strain)
      Bekinda (IBS-D)
      SYN-010
      Tenapanor
      Market size by End User
      Hospital
      Research

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Irritable Bowel Syndrome (IBS) Therapeutics market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Irritable Bowel Syndrome (IBS) Therapeutics market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Irritable Bowel Syndrome (IBS) Therapeutics companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Irritable Bowel Syndrome (IBS) Therapeutics submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Irritable Bowel Syndrome (IBS) Therapeutics are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Irritable Bowel Syndrome (IBS) Therapeutics market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now